Opthea/OPT

$3.03

2.36%
-
1D1W1MYTD1YMAX

About Opthea

Opthea Limited is an Australia-based biotechnology company. The Company is engaged in the development and commercialization of therapies primarily for eye disease. The Company’s lead asset, OPT-302, is a novel biologic inhibitor of VEGF-C and VEGF-D, for use in combination with VEGF-A inhibitors for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The Company’s principal activities include the progression of the Company’s Phase III registration trials of OPT-302 for wet AMD. It also manufactures OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. The Company’s development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
Ticker
OPT
Sector
Healthcare
Trading on
NASDAQ
Industry
Business Services
CEO
Frederic Guerard
Employees
-
Headquarters
Melbourne, Australia
Website
opthea.com

Opthea Metrics

BasicAdvanced
$252.96M
Market cap
-
P/E ratio
-$2.42
EPS
0.41
Beta
-
Dividend rate

What the Analysts think about Opthea

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 6 analysts.
327.72% upside
High $16.16
Low $8.08
$3.03
Current price
$12.96
Average price target

Opthea Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-65.4M
-15.06%
Profit margin
0%
-

Opthea Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 678.68%
QuarterlyAnnual
Q4 22
Q2 22
Q4 23
Q2 23
Q4 24
Actual
-$1.17
-$1.74
-$1.97
-$1.86
-
Expected
-$0.10
-$0.19
-$0.13
-$0.24
-$0.85
Surprise
1,068%
824.32%
1,413.85%
678.68%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

Buy or sell Opthea stock

Buy or sell Opthea stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing